ReviewEndocrine pathology2008
Familial non-medullary thyroid carcinoma: an update.
Review in Endocrine pathology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 81 citations in OpenAlex.
- Familial Non-Medullary Thyroid Carcinoma in Pediatric Age: Our Surgical Experience.World journal of surgery · 2021Article
- Geographic influences in the global rise of thyroid cancer.Nature reviews. Endocrinology · 2020Review
- Anaplastic thyroid cancer: How far can we go?EXCLI journal · 2020Review
- Genome-wide association and expression quantitative trait loci studies identify multiple susceptibility loci for thyroid cancer.Nature communications · 2017Article
- A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes.Journal of genetic counseling · 2017Review
- Three siblings with familial non-medullary thyroid carcinoma: a case series.Journal of medical case reports · 2016Article
- HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.Journal of the National Cancer Institute · 2016Article
- Clinicopathologic characteristics of familial versus sporadic papillary thyroid carcinoma.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2015Article
- The surgical management of thyroid cancer.Rambam Maimonides medical journal · 2014Article
- Villous papillary thyroid carcinoma: a variant associated with marfan syndrome.Endocrine pathology · 2012Article
- The clinical management in familial adenomatous polyposis deserves continuous monitoring for thyroid carcinoma.BMJ case reports · 2012Article
- Familial follicular cell-derived thyroid carcinoma.Frontiers in endocrinology · 2012Article
- The differential diagnosis of familial lentiginosis syndromes.Familial cancer · 2011Review
- Rare and unusual endocrine cancer syndromes with mutated genes.Seminars in oncology · 2010Review
- Familial follicular cell tumors: classification and morphological characteristics.Endocrine pathology · 2010Review
- Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes.Best practice & research. Clinical endocrinology & metabolism · 2010Review
- Oncocytes, oxyphils, Hürthle, and Askanazy cells: morphological and molecular features of oncocytic thyroid nodules.Endocrine pathology · 2010Review
- Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies.Journal of oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial thyroid cancer can arise from follicular cells (familial non-medullary thyroid carcinoma (FNMTC)) or from the calcitonin-producing C-cell (familial medullary thyroid carcinoma). This is usually a component of multiple endocrine neoplasias (MEN) IIA or IIB, or as pure familial medullary thyroid carcinoma syndrome. The genetic events in the familial C-cell-derived tumors are known and genotype-phenotype correlations are well established. In contrast, the case for a familial predisposition of non-medullary thyroid carcinoma is only now beginning to emerge. Although the majority of papillary (PTC) and follicular thyroid carcinomas (FTC) are sporadic, familial tumors account for over 5% of cases. The presence of multifocal papillary carcinoma is a common feature of FNMTC. The familial follicular cell-derived tumors or non-medullary thyroid carcinomas encompass a heterogeneous group of diseases, including diverse syndromic-associated tumors and non-syndromic tumors. Based on clinico-pathologic findings, FNMTC is divided into two groups. The first includes familial syndromes characterized by a predominance of non-thyroidal tumors, such as familial adenomatous polyposis (FAP), PTEN hamartoma tumor syndrome (PHTS), Carney complex type 1, and Werner syndrome. The second group includes familial syndromes characterized by a predominance of NMTC, such as pure familial (f) PTC with or without oxyphilia, fPTC with papillary renal cell carcinoma, and fPTC with multinodular goiter. Some characteristic morphologic findings should alert the pathologist of a possible familial cancer syndrome, which may lead to further molecular genetic evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.